Clinical trial · Interventional
Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered Orally to Subjects With Chronic Lymphocytic Leukemia
NCT00234481CI-TRIAL-00001508terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study closed due to slow enrollment
Summary
Brief summary (as posted)
The purpose of this study is to assess the safety and tolerability of different doses of XL844 when given orally to adults with recurrent or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Small Lymphocytic Lymphoma | Small Lymphocytic Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| XL844 | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with recurrent or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) * Prior treatment with at least 2 systemic chemotherapy regimens for CLL * Life expectancy of \>3 months * Adequate liver and kidney function * Absolute neutrophil count ≥500/mm3; platelets ≥50,000/dL; hemoglobin ≥9 g/dL * Willing to use accepted method of contraception during the course of the study * Negative pregnancy test (females) * Written informed consent Exclusion Criteria: * Chemotherapy or radiotherapy within 4-6 weeks of the start of treatment (depending on the therapy) * Investigational drug within 30 days of the start of treatment * Uncontrolled intercurrent illness such as infection or cardiovascular disease * Pregnant or breastfeeding women * Subjects known to be HIV positive
References
Publications (0)
Data not yet available
No reference posted for this study.